After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development. News:&nbsp;<a href="https://www.nature.com/articles/d41586-021-01661-0" rel="noopener noreferrer" target="_blank">CureVac COVID vaccine let-down spotlights mRNA design challenges</a>News Feature:<a href="https://www.nature.com/articles/d41586-021-00019-w" rel="noopener noreferrer" target="_blank">&nbsp;How COVID unlocked the power of RNA vaccines</a> ﻿<a href="https://go.nature.com/get-the-nature-briefing?utm_source=coronapod&amp;utm_medium=podcast&amp;utm_campaign=shownotes" rel="noopener noreferrer" target="_blank">Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.</a> &#10;&nbsp; <hr>See <a style='color: grey; ' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for privacy and opt-out information.

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

CureVac disappoints in COVID vaccine trial

Springer Nature Limited